Q3 FY2026 Pharmacy Retail Expansion and Margin Snapshot

Pharmacy Retail (India) — Sector analysis (with retail pharmacy + distribution adjacencies) This report synthesizes the operating reality of India’s organized pharmacy retail and allied healthcare distribution using two live company windows: (1) a scaled omni-channel pharmacy retailer (MedPlus) and (2) a national healthcare products distributor expanding into MedTech (Entero). Together they highlight the sector’s current shape: formalization and consolidation, expanding private label economics, cluster-led physical networks enabling hyperlocal delivery, and an increasing role for large-scale distributors with improving service levels and working-capital discipline—set against regulatory noise (wage codes, GST changes) and new consumer-facing competition (quick commerce).

---

A. Industry overview & market landscape

1) What the “Pharmacy Retail” ecosystem looks like (as evidenced by company disclosures) Even though the sector label is “Pharmacy Retail,” the extracted dataset spans two tightly linked layers of the same healthcare commerce value chain:

• **Retail pharmacy (consumer-facing)**: store networks + omni-channel ordering and delivery; mix of **acute + chronic** prescriptions and OTC/non-pharma.
• **Healthcare products distribution (B2B)**: distributors supplying retail pharmacies, hospitals, and other healthcare institutions across districts and states; increasingly consolidating into national platforms.
• **Adjacencies**: **Diagnostics subscription/plans** (as a loyalty/health services layer), **MedTech distribution**, and private label (pharma + non-pharma, and eventually home healthcare devices).

A key structural insight explicitly stated by a retailer: **online-only models largely skew to chronic therapies**, while **stores address the full market (acute + chronic)**. One disclosure cites chronic as **~37% of the market** (Technopak 2020 citation), implying the remaining majority is acute/emergent and structurally advantaged for hyperlocal fulfillment.

2) Market size and growth (only where explicitly quantified) Direct market sizing is provided for distribution/MedTech rather than retail pharmacy:

• **Healthcare products distribution TAM**: **$33.2bn (FY23)** with **10–11% CAGR (FY23–FY28)**.
• **MedTech market size**: **>₹3 lakh crores**.
• **Industry consolidation trajectory (distribution)**: share of large/national distributors expected to rise from **8–10% (FY23)** to **20–30% by FY28**, implying **25–30% CAGR** for large players (as per cited expectation).

These numbers frame a sector where **formal, scaled platforms** can grow much faster than the underlying consumption market by taking share from fragmented incumbents.

3) Market structure & segmentation (observable in the two-company sample)

**Retail pharmacy segmentation (MedPlus lens):** - Product buckets: **Branded Pharma**, **Branded Non-Pharma**, **Private Label (PL) Pharma**, **PL Non-Pharma/FMCG**, plus “Others” (franchise, optical, diagnostics, membership/service fee). - Channel buckets: **store-based** and **omni-channel** (online ordering fulfilled via store network, delivery hubs, hyperlocal delivery). - Geographic mix (revenue share by store location): Metro, Tier-1, Tier-2, Tier-3+; with gradual shift towards non-metros over time.

**Distribution segmentation (Entero lens):** - Customer types: retail pharmacies, hospitals. - Product lines: broad pharma distribution plus accelerating **MedTech** distribution (and smaller private label in home healthcare). - Growth composition: **organic + acquisitions** (with explicit decomposition and “like-to-like” adjustments for accounting and divestments).

4) Geographic distribution and regional dynamics - A scaled retailer reports presence across **13 states and 1 union territory**, reaching **~800 cities** with **5,100+ stores**. - A scaled distributor reports presence in **21 states**, **~50 cities**, serving **505 districts** through **131 warehouses**.

A common pattern emerges: **dense logistics footprints** (stores or warehouses) are the operational core enabling service levels (fast delivery, frequent replenishment) and acting as an entry barrier.

5) Market maturity and lifecycle The disclosures collectively suggest a sector in a **formalization/consolidation phase**: - Retail: ongoing rapid store additions, private label penetration rising, omni-channel scaling. - Distribution: aggressive M&A now tapering into integration mode; explicit commentary that **large distributors’ share is expected to rise sharply** by FY28.

---

B. Financial & economic profile

1) Sector “two-layer” economics: retail vs distribution The two-company snapshot shows structurally different margin stacks:

• **Retail pharmacy**: higher gross margins (mid‑20s %) but meaningful opex and rent; operating EBITDA ~5% at consolidated/segment level for a mature network.
• **Distribution**: low gross margins (~10%) and EBITDA margin around ~4% even at scale; the business is optimized via service, scale, and working-capital discipline.

The following table places Q3 FY26 profitability side-by-side using the disclosed metrics and definitions (note: MedPlus also discloses a higher “EBITDA” line that includes rent/lease accounting effects; its “Operating EBITDA” is the cleaner operating metric used here).

| Metric (Q3 FY26) | MedPlus (Consolidated) | MedPlus (Pharmacy Retail segment) | Entero (Consolidated) | |---|---:|---:|---:| | Revenue | ₹18,061m | ₹17,714.8m | ₹1,706.5cr | | Gross margin % | 26.2% | 25.1% (pharmacy GM%) | 10.1% | | Operating EBITDA margin | 5.4% | 5.2% | 4.0% | | PAT margin (reported) | 3.2% | (segment PAT not given) | 2.0% (reported), 2.3% ex one-off | | One-offs referenced | ₹70.59m wage/labour code cost | same | Exceptional ₹8.2cr (₹6.1cr PAT impact) |

Interpretation: retail’s **gross margin headroom** is materially higher, but final profitability converges closer to distribution due to rent and store/cluster costs; both businesses are actively managing one-off wage code impacts.

2) Growth trajectory and momentum

**MedPlus (consolidated)** - Q3 FY26 revenue **₹18,061m**, **+15.7% YoY**, **+7.5% QoQ**. - Trend (₹m): **15,614 (Q3FY25) → 15,096 (Q4FY25) → 15,426 (Q1FY26) → 16,793 (Q2FY26) → 18,061 (Q3FY26)**. - 9M FY26 revenue **₹50,280.8m**, **+8.7% YoY**; gross margin expanded sharply to **26.1%** from **23.7%**.

**Entero** - Q3 FY26 revenue **₹1,707cr**, **+26% YoY**, **+9% QoQ**. - Like-to-like growth **+28.5% YoY** (after adjusting for net-margin recognition and divestment), with **organic LFL +17.1% YoY** (highest organic growth YTD). - 9M FY26 revenue **₹4,681cr**, **+25% YoY** (deck: +24.6%).

A notable cross-sector point: Entero references **IPM growth ~12%** in Q3, while reporting organic/LFL multiples above industry (e.g., Q3 organic LFL multiple **1.4x** vs IPM).

3) Profitability levels: margins, ranges, and what drives them

**Retail (MedPlus)** - Consolidated gross margin **26.2%** in Q3 FY26, **+110 bps YoY**. - Operating EBITDA **₹968m (5.4%)**, includes a **₹70.59m** non-recurring wage/labour code charge. - Consolidated PAT **₹577.9m**, PAT margin **3.2%**. - Pharmacy retail segment: operating EBITDA **₹925m**, margin **5.2%**; pharmacy GM% **25.1%**. - Diagnostics segment: operating EBITDA margin **15.5%** on revenue **₹326.7m**. - CEO comment: sees no reason not to reach **~6% pharmacy operating margin over time** (no timeline).

**Distribution (Entero)** - Gross margin **10.1%** (Q3 FY26), **+30 bps YoY**; QoQ GM down ~10 bps as a **one-time GST incentive = 17 bps** from pharma companies was not repeated/offset. - EBITDA **₹68cr**, margin **4.0%** (flat QoQ; up ~29–30 bps YoY). - PAT (excluding wage code) **₹40cr**, margin **2.3%**; reported PAT **₹34cr**, margin **2.0%** due to exceptional wage code. - Guidance reiterated: FY26 **EBITDA margin north of 4%**.

4) Return profiles (ROCE/ROE) and what they signal - **MedPlus ROCE (annualized)** improved to **24.2% in Q3FY26** (from **22.5% Q2FY26**, and **18.7% Q3FY25**). This is consistent with a maturing store base + improving same-store growth and margin stability. - **Entero ROCE**: **14.8% in Q3** vs **13.8% in Q2** (deck shows **12.3% in Q3FY25**). ROE (excluding labour code) cited at **12.3%** vs **11.0%** last quarter.

The retailer’s ROCE is higher, reflecting store-level economics and private label, while the distributor’s is lower but improving with scale and integration benefits.

5) Working capital and cash conversion: a major differentiator Working capital is a central KPI in both models, but the drivers differ (inventory at stores vs receivables/payables at distribution).

**MedPlus** - Net working capital: **53 days** (Q3), stable vs prior quarter trend improvement (chart: **61 → 63 → 59 → 53 → 53** across Dec‑24, Mar‑25, Jun‑25, Sep‑25, Dec‑25). - Inventory: warehouse **34 days**; year‑1 stores **103 days**; stores >12 months **~35 days**. - Q3 FY26 operating cash flow **₹905m**; **OCF/Operating EBITDA 93.5%**. - Free cash flow Q3 FY26 **₹(93)m** (negative), reflecting capex/lease payments/working capital movements. - Closing cash & bank **₹6,080m**; included **₹430m** withdrawn from fixed deposits. - Working capital increase in Q3 cash bridge: **(₹685m)**.

**Entero** - NWC days (LFL): **61 days** in Q3 FY26 vs **63 days** in Q2 (and ~66 days in Q1). - Reported NWC: **64 days** vs **63** last quarter; management attributes this to tax gross-up change as sale GST rate changed **12% → 5%** in Q3, masking operational improvement (stated: **2 days inventory** + **1 day receivables** reduction). - Q3 FY26 OCF **₹49cr**; 9M FY26 OCF **₹(8.4)cr** (negative YTD), but management targets FY26 OCF **~₹100cr**.

Interpretation: both models are pushing working capital down. Retail’s working capital is heavily influenced by **new store inventory** (103 days in Year‑1 stores). Distribution’s working capital is driven by receivables/inventory and is sensitive to GST/structural accounting changes.

---

C. Competitive structure & dynamics

1) Market concentration and scale signals Even within a fragmented sector, the companies repeatedly emphasize scale as a moat: - Retail: “**2nd largest pharma retailer**” with **5,100+ stores**, **48k+ SKUs** in warehouses, **~800 cities**, **28k+ employees**. - Distribution: **97,600+ retail pharmacies served (9M)**, **3,200+ hospitals (9M)**, **505 districts**, **131 warehouses**, **89,200+ SKUs**, **3,100+ manufacturers**.

The structural competition appears to be between: - Organized chains vs independent pharmacies (retail). - Large national distributors vs regional/local distributors (distribution). - Retailers vs emerging convenience channels (quick commerce) and online-first players.

2) Differentiation strategies and moats (observed) **Retail moats** - Hyperlocal network enabling **<2-hour delivery**. - Stores as both fulfillment points and **customer acquisition/branding** reducing CAC. - Cluster densification + warehouse sweating strategy. - Private label economics: very high gross margin bands in PL pharma (**~65–70% net basis**) and PL non-pharma (**~25–28%**, also stated **25–30%**).

**Distribution moats** - Service levels: deliveries **2–3 times per day** mentioned as a growth driver. - “One buyer/one supplier” convenience with broad portfolio. - Scale benefits and consolidation trend: expectation that national distributors’ share rises to **20–30% by FY28**. - MedTech expansion leveraging the same warehouse footprint and manufacturer relationships (Abbott, Roche examples cited).

3) Competitive intensity and substitutes (as discussed) - **Quick commerce** is monitored by the retailer; the company has **ramped up offerings** and claims capability to improve further. - **PharmEasy returning** was explicitly downplayed by the distributor as not changing dynamics much. - Private label substitution risk is acknowledged in **pharma** (prescription-bound), while **non-pharma substitution** is described as **very low** and more incremental.

4) Consolidation and M&A Consolidation is explicit in distribution: - Entero closed **7 acquisitions YTD**, with **₹1,025cr proforma revenue** of deals closed. - Acquisition mix (proforma): **MedTech 61% | Specialty Pharma 13% | Geographic expansion 19% | Trade generics 7%**. - EV/EBITDA multiples: **single digits**. - Management now expects **2–3 quarters** focusing on integration rather than more “meaningful” acquisitions.

Retail consolidation is implicit via rapid store rollout and franchise experimentation, rather than M&A.

---

D. Operational characteristics

1) Retail operating model benchmarks (store network economics) MedPlus provides unusually granular store cohort economics that can be treated as industry-leading benchmarks for organized retail pharmacy.

Key operating facts: - Stores as of **31-Dec-25: 5,112**. - Store age mix: **Year 2+ 77% | Year 1 9% | Year 0 14%**. - ~**1,173 outlets <24 months** (less than 24M) and expected to be P&L accretive on maturity.

Cohort performance (>12 months stores): - Q3FY26 revenue from >12-month stores: **₹16,300m**, **96%** of pharmacy revenues. - Store-level EBITDA margin (Q3FY26): **12.4%** ( >24 months **12.6%**; 13–24 months **8.8%** ). - After allocating all non-store costs, operating EBITDA margin for >12 months cohort: **5.8%**; operating EBITDA **₹967m**.

The following table captures the disclosed trend in same-store-like growth and unit economics for mature stores, which is critical for judging whether rapid store expansion is value-accretive.

| Metric (stores >12 months) | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | |---|---:|---:|---:|---:|---:| | Store-level revenue growth (YoY) | 4.4% | -0.9% | -0.2% | 2.2% | 10.5% | | Store-level EBITDA margin | 11.0% | 11.5% | 10.9% | 11.8% | 12.4% | | Store-level operating ROCE | 61.7% | 59.2% | 59.8% | 68.6% | 77.7% | | Operating EBITDA (₹m) | 815 | 817 | 727 | 877 | 967 | | Operating EBITDA margin (after non-store costs) | 5.6% | 5.8% | 5.1% | 5.6% | 5.8% |

Interpretation: the sharp rebound to **10.5%** YoY growth in Q3FY26 (after several weak quarters) combined with expanding store-level margins suggests the network is regaining momentum; this matters because new store rollouts are dilutive early due to **Year‑1 inventory and ramp costs**.

2) Retail inventory and warehouse “sweating” logic - Warehouse inventory days: **34**; mature store inventory ~**35** days; **Year‑1 store inventory 103 days**—a key driver of working-capital drag during aggressive expansion. - Strategy explicitly stated: **densify existing states** first to **sweat warehouse assets**, then move to adjacent states. - Warehousing update: **60–70% of new warehouses** operationalized; remaining in next **2 quarters**. Manpower recruitment completed; expects **no significant ramp-up** of expenses related to those warehouses.

3) Omni-channel operating KPIs (retail) - Omni-channel revenue trend (₹m): **870 (Q3FY25) | 873 (Q4FY25) | 863 (Q1FY26) | 882 (Q2FY26) | 904 (latest shown)**. - Omni-channel share shown as **8.0%** of total revenue. - Delivery hubs trend: **636 | 598 | 637 | 690 | 699**. - Online pincodes trend: **2,867 | 2,858 | 2,935 | 3,043 | 3,021**.

4) Diagnostics as an adjacency (retail-linked services) - Diagnostics revenue: **₹326.7m (Q3FY26)** vs **₹274.7m (Q3FY25)**. - Diagnostics operating EBITDA: **₹50.7m** vs **₹22.1m** YoY; operating EBITDA margin **15.5%**. - Gross plans/day: **Oct 506**, **Nov 529**, **Dec 528**. - Active plans: **180,000** (as of 31-Dec) covering **368,000 lives**; up from **170,000 plans** covering **351,000 lives** as of 30-Sep. - On-time renewal rate: **23% in Q3** vs **24%** previous quarter.

Interpretation: diagnostics subscriptions show scale-up (plans/lives up) and strong margins, but renewal rates in the low‑20s highlight churn/engagement as a key KPI for long-term annuity economics.

5) Distribution operating model benchmarks Entero’s operational footprint is a scale moat: - **131 warehouses** (vs **103** in 9M FY25). - Coverage: **505 districts** (vs **492**). - Retail pharmacies served: **97,600+** (vs **84,900+**). - SKUs: **89,200+** (vs **76,600+**). - Manufacturers: **3,100+** (vs **2,500+**). - Hospitals: **3,200+** (flat vs **3,200+**).

Capex intensity: - Warehouses are leased; setup capex per warehouse **~₹30–40 lakhs**. Procurement/logistics: - Supplies received locally from **local CFAs**; negotiations centralized; local supply avoids redistribution cost. - Hub-and-spoke example: large **Mumbai** warehouse serving Mumbai + nearby (Thane).

---

E. Growth dynamics & drivers

1) Retail growth drivers (as stated and quantified)

**a) Store expansion + densification** - Q3FY26: **228 openings**, **46 closures**, net **+182**. - Of 46 closures: **17 relocations**, **10 franchisee withdrawals**, **others 19** (deck), while management also referenced **12** closed for other reasons on call (the combined closure explanations reconcile via the deck split). - Net additions beyond Tier‑One: **116** (explicit tilt toward non-metros). - Strategy: deepen penetration in existing states, sweat warehouse assets, then expand adjacent states; new state mentions: **Chhattisgarh started**, **Kerala started**.

**b) SSSG / mature store growth rebound** - Mature-store YoY growth improved to **10.5%** in Q3FY26, attributed to: - **Lower base** effects. - **Change in store incentive structure**: from predominantly private label sales focus to include **total sales (branded + private label)** at store level.

**c) Private label expansion** - Private label share of total revenues (Q3FY26): **22.2%**. - PL pharma: **11.6%** - PL FMCG/non-pharma: **10.6%** - Private label assortment: **1500+ SKUs** (Pharma **850+**, Non-pharma **650+**). - Expansion into food, wellness, cold-pressed oils. - High net margins by category (management “net basis”): - Branded pharma: **~13–14%** - Branded non-pharma: **~13–14%** - PL pharma (old + MedPlus brand): **~65–70%** - PL non-pharma: **~25–28%** (also stated **25–30%**) - Rule of thumb reaffirmed: **every 50 bps increase in private label leads to margin accretion**.

**d) Omni-channel leverage** - Fulfillment advantage: **<2-hour delivery**, using **5,112** hyperlocal stores; stores serve as marketing nodes reducing CAC.

2) Distribution growth drivers (as stated and quantified)

**a) Organic growth above industry** - Q3 organic growth: **14.2%**; organic growth (LFL) **17.1%** vs IPM growth **12%**. - Organic growth multiple vs IPM: **Q1 1.7x | Q2 1.8x | Q3 1.4x | 9M 1.6x**.

**b) Inorganic growth via acquisitions** - Growth decomposition: - Q3FY25 **₹1,359cr → Q3FY26 ₹1,707cr**: - Organic **14.2%** - Calendarization **0.6%** - New acquisitions **10.7%** - 9MFY25 **₹3,757cr → 9MFY26 ₹4,681cr**: - Organic **12.2%** - Calendarization **7.2%** - New acquisitions **5.2%**

**c) MedTech expansion** - Post-integration, MedTech annualized revenue expected to **cross ₹1,000cr**. - MedTech expected to be **~15% of business** once ₹1,000cr is in books. - Expected margin uplift (pro forma) from MedTech integration: - Gross margin: **+70 to +90 bps** (from **10.2% → 10.9% to 11.1%**) - EBITDA margin: **+50 to +75 bps** (from **4.0% → 4.5% to 4.75%**)

**d) Service-level and platform value proposition** - Delivery frequency cited: **2–3 times per day**. - “One buyer/one supplier” convenience and broad portfolio.

---

F. Risk landscape

1) Regulatory and policy risks **New Labour/Wage Codes** - MedPlus: one-time charge **₹70.59m (~₹7cr)** as past service cost; rules/notifications “still not final”; monitoring continues. - Entero: exceptional item **₹8.2cr**, PAT impact **₹6.1cr net of tax**; management expects **no material ongoing margin effect**.

**GST-related comparability / rate changes** - Retail: company stopped providing certain MRP growth metrics due to a **flat GST reduction ~6.5–7%** affecting comparability. - Distribution: sale GST rate changed **12% → 5%** in Q3 affecting reported NWC days due to tax gross-up mechanics; operationally, inventory and receivables days improved.

2) Competitive and disruption risks - **Quick commerce** threatens acute/instant needs; retail chain is monitoring and has ramped offerings. - Online and platform competition (e.g., **PharmEasy**) is cited by distributor as not materially changing dynamics. - **Private label substitution**: in pharma, substitution constrained by prescriptions; acknowledged as a watch item; non-pharma substitution described as low and incremental.

3) Execution risks - Retail: rapid store openings create working-capital strain due to **Year‑1 inventory (103 days)**; also closure/relocation management. - Distribution: integration risk from **7 acquisitions YTD**; margin uplift depends on execution; MedTech requires **demand generation costs** (qualified manpower, marketing/promotion), pushing “other expenses” higher.

4) Financial risks - Distribution: interest costs rising due to acquisitions and IPO cash usage; net debt **~₹200cr** with cash **~₹250cr** (net cash-ish but leverage present at operating level). - Retail: lease liabilities and rent structure remain material; free cash flow can be negative in expansion quarters (Q3 FY26 FCF **₹(93)m**).

---

G. Capital allocation & investor returns

1) Capex intensity and expansion spend - Retail (MedPlus): capex in Q3 FY26 cash bridge **₹(316)m**; lease liability payments **₹(682)m**. - Distribution (Entero): “not capital intensive”; warehouses leased; capex per warehouse **~₹30–40 lakhs**.

2) M&A and consolidation capital allocation (distribution) - Entero closed acquisitions including **Anand Medilink (Pune)**, **Ace Cardiopathy**, **Bioaide Technologies**, **Anand Chemiceutics (MedTech; closed Feb 07, 2026)**. - **7 acquisitions closed YTD**; proforma revenue **₹1,025cr**: - H1FY26: **₹215cr** (3 deals) - Q3FY26: **₹385cr** (3 deals) - Jan–Feb’26: **₹425cr** (1 deal) - Management: not looking for more “meaningful” acquisitions for next **2–3 quarters**, focusing on integration; no equity raise planned (debt may move).

3) Cash generation and OCF focus - MedPlus: Q3 FY26 OCF **₹905m**, high conversion vs operating EBITDA (93.5%); but FCF negative due to working capital/lease/capex. - Entero: Q3 FY26 OCF **₹49cr** positive; 9M FY26 OCF **₹(8.4)cr**; targets FY26 OCF **~₹100cr** (implying strong Q4).

---

H. Future outlook & projections (only what is explicitly supported)

1) Retail (MedPlus) outlook statements - Gross margin expected to **remain at the same level** (no numeric guidance beyond stability). - SSSG visibility: “clear visibility for next **1 quarter**.” - Store openings next year: should be “at least similar numbers of this year” (informal). - Margins: CEO sees no reason not to reach **~6% pharmacy operating margin** over time (no timeline). - Warehouses: remaining **30–40%** of new warehouses to be operationalized over next **2 quarters**, with **no significant expense ramp-up** expected.

2) Distribution (Entero) outlook and reiterated guidance For FY26: - Like-to-like growth guidance: **30%** for full year (management reiterates “on track”). - EBITDA margin: **north of 4%** (on track). - Operating cash flow: **~₹100cr** (shooting for; implies >₹100cr in Q4 given YTD).

Next year: - Broad ranges to be provided in **Q4** call. - Growth expected **not to materially come down** due to full-year acquisition impact from H2FY26 + organic growth.

3) Structural themes likely to shape the next phase (implied by strategies) - Continued **share shift to organized** retail and distribution platforms. - Private label penetration increasing as a margin lever (especially in non-pharma; pharma capped by prescriptions). - Cluster densification and hyperlocal fulfillment as defense vs quick commerce. - MedTech distribution becoming a higher-margin mix driver within distributor models.

---

I. Company-by-company profiles

MedPlus Health Services Limited (NSE: MEDPLUS)

Business description and positioning A scaled omni-channel pharmacy retailer claiming to be the **2nd largest pharma retailer in the country**, with **5,100+ stores** across **13 states and 1 union territory**, reaching **~800 cities**, employing **28k+** people, and handling **48k+ SKUs** across warehouses. The model emphasizes stores as both demand generators and hyperlocal fulfillment nodes enabling **<2-hour delivery**.

Scale and network metrics - Stores (31-Dec-25): **5,112** - Warehouses SKUs: **48k+** - City reach: **~800** - Employees: **28k+** - Store-level ROCE: **>70%**; stores >12 months operating ROCE **77.7%** (Q3FY26)

Financial performance (Q3 FY26 and trends) Consolidated revenue **₹18,061m** in Q3 FY26 (YoY **+15.7%**, QoQ **+7.5%**). Gross margin **26.2%** (up **110 bps YoY**). Operating EBITDA **₹968m (5.4%)** including **₹70.59m** one-off wage code cost. PAT **₹577.9m (3.2%)**.

To show the sequential progression across the last five quarters, the following table reproduces the disclosed consolidated trend.

| Consolidated metric | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | |---|---:|---:|---:|---:|---:| | Revenue (₹m) | 15,614 | 15,096 | 15,426 | 16,793 | 18,061 | | Gross margin % | 25.0% | 26.6% | 26.1% | 26.1% | 26.2% | | Operating EBITDA (₹m) | 799 | 803 | 728 | 887 | 968 | | Operating EBITDA margin | 5.1% | 5.3% | 4.7% | 5.3% | 5.4% | | ROCE (annualized) | 18.7% | 19.3% | 17.0% | 22.5% | 24.2% |

Interpretation: revenue growth accelerated sharply into Q3FY26 while margins stayed stable-to-improving, translating into a material ROCE uplift.

Segment performance (Q3 FY26) - **Pharmacy Retail**: Revenue **₹17,714.8m**, Operating EBITDA **₹925.0m**, margin **5.2%**. - **Diagnostics**: Revenue **₹326.7m**, Operating EBITDA **₹50.7m**, margin **15.5%**. - **Others**: Revenue **₹19.7m**, Operating EBITDA **₹(8.2)m**, margin **-41.5%**.

Unit economics and cohort dynamics - Mature stores (>12 months) generate **96%** of pharmacy revenues (₹16,300m of ₹~17.7bn). - Store-level EBITDA margin **12.4%** (Q3FY26); >24 months **12.6%**, 13–24 months **8.8%**. - After allocating non-store costs, operating EBITDA margin for mature stores **5.8%**.

Store rollout and footprint strategy - Q3FY26: **228** openings, **46** closures; net **+182**. - Closures: relocation **17**, franchise withdrawals **10**, others **19** (deck); management noted **17** relocations and **12** closed for other reasons. - **7** stores in process of converting into franchisee; **10** franchisee withdrawals. - Net adds beyond Tier‑One: **116**. - Strategy: **cluster-based densification**, sweat warehouses, then adjacent states; newer state progress: **Chhattisgarh** and **Kerala** started.

Private label strategy and economics - Private label share of total revenues (Q3FY26): **22.2%** - PL pharma **11.6%**, PL non-pharma **10.6%** - Private label assortment: **1500+ SKUs** (pharma **850+**, non-pharma **650+**) - Margin bands (net basis): - Branded pharma **~13–14%** - Branded non-pharma **~13–14%** - PL pharma **~65–70%** - PL non-pharma **~25–28%** (also **25–30%**) - PL pharma GMV share: **18.9%** currently vs **7.9%** prior to MedPlus branded pharma launch (launched in last year’s Q1). - Therapy mix (PL pharma portfolio): **~55% chronic**, **~40–45% acute**; top five therapeutic areas; chronic examples: diabetes, cardiovascular, hypertension.

Omni-channel and customer metrics - Omni-channel revenue shown around **₹904m** latest (vs ₹870m Q3FY25); share **8.0%** of total. - Delivery hubs **699** latest; online pincodes **3,021** latest. - Pharma members: **46–47 lakhs**.

Working capital, cash, and accounting notes - NWC **53 days**; warehouse inventory **34 days**; Year‑1 stores **103 days**. - Q3FY26 OCF **₹905m**; closing cash **₹6,080m**. - Ind AS adjustment disclosure (Q3FY26) indicates large lease-accounting effects: - D&A reported **₹(727.4)m** with Ind AS impact **₹(526.6)m** → adjusted **₹(200.8)m** - Finance costs reported **₹(308.3)m** with Ind AS impact **₹(308.5)m** → adjusted **₹0.2m** - PAT reported **₹577.9m** with Ind AS impact **₹(115.2)m** → adjusted **₹693.1m**

Management outlook / guidance (as stated) - GM expected to remain at same level. - Store opening next year at least similar to this year (informal). - Clear SSSG visibility for next 1 quarter. - Long-run margin aspiration: ~**6%** pharmacy operating margin (no timeline). - Wage code impact recognized as one-time; monitoring regulatory finalization.

---

Entero Healthcare Solutions Limited (NSE: ENTERO)

Business description and positioning A scaled healthcare products distributor servicing retail pharmacies and hospitals across India, with a national warehouse network and an explicit strategy to consolidate via acquisitions and expand into MedTech distribution. The company positions itself as outperforming IPM growth through service levels (including **2–3 deliveries/day**), broad assortment, and “one buyer/one supplier” convenience.

Scale and footprint - Retail pharmacies served: **97,600+** (9M) - Hospitals: **3,200+** (deck; call also mentioned 3,000+) - Districts: **505** - Warehouses: **131** (vs 103 in 9M FY25) - SKUs: **89,200+** (call also referenced 87,000; deck 89,200+) - Manufacturers: **3,100+** - Presence: **~50 cities**, **21 states** - Total warehouse area: **6,22,821 sq ft**

Financial performance (Q3 FY26) - Revenue **₹1,706.5cr**, **+26% YoY**, **+9% QoQ**. - Gross profit **₹172.6cr**, GM **10.1%** (+30 bps YoY). - QoQ GM down 10 bps due to absence/offset of a **one-time GST incentive = 17 bps** previously received from pharma companies. - EBITDA **₹67.8cr**, margin **4.0%** (+~30 bps YoY). - PAT: - Ex wage code: **₹40cr**, margin **2.3%** (vs ₹29cr, 2.2% in Q3FY25). - Reported: **₹33.9cr**, margin **2.0%**, with exceptional wage code item **₹8.2cr** (PAT impact **₹6.1cr** net of tax).

9M FY26 performance - Revenue **₹4,681cr** (+25% YoY). - Gross profit **₹473cr (10.1%)** vs **₹356cr (9.5%)**, +64 bps. - EBITDA **₹180cr (3.8%)** vs **₹123cr (3.3%)**, +58 bps.

Working capital and cash flow - NWC (LFL) **61 days** in Q3FY26 vs **63** in Q2; ~66 in Q1. - Reported NWC **64 days** vs **63**, impacted by GST rate change **12% → 5%** affecting tax gross-up; masked improvement of **2 days inventory** + **1 day receivables** reduction. - OCF: Q3FY26 **₹48.9cr**; 9MFY26 **₹(8.4)cr**; FY26 target **~₹100cr**. - OCF bridge (Q3FY26): PBT **40.4**, wage code **8.2**, non-cash/other **24.5**, WC change **(15.6)**, taxes **(8.7)** → OCF **48.9** (₹cr).

Capital structure - Net debt **~₹200cr** - Cash **~₹250cr** - Interest costs rising due to acquisition funding and reduced IPO cash interest income.

Acquisition and MedTech strategy - Closed acquisitions: Anand Medilink (Pune), Ace Cardiopathy, Bioaide Technologies, Anand Chemiceutics (closed Feb 07, 2026). - **7 acquisitions closed YTD**; proforma revenue of deals closed **₹1,025cr**. - Acquisition mix (proforma): **MedTech 61% | Specialty Pharma 13% | Geographic expansion 19% | Trade generics 7%**. - EV/EBITDA acquisition multiples: **single digits**. - MedTech: - Annualized revenue expected to **cross ₹1,000cr** post integration. - Mix expected ~**15%** once in books. - Pro forma margin uplift: GM **+70–90 bps**; EBITDA **+50–75 bps**. - Growth levers: pan-India exclusive distribution; leverage **130/131** warehouses and supplier relationships (Abbott, Roche examples). - MedTech private label exists in home healthcare, “still small,” to be pushed over time. - Near-term stance: major acquisitions done; next **2–3 quarters** to integrate and improve margins/cash flows; no equity raise planned.

Management guidance / outlook - FY26 like-to-like growth **30%** (on track). - FY26 EBITDA margin **north of 4%** (on track). - FY26 OCF **~₹100cr** (shooting for). - Next year guidance to be provided in Q4; growth expected not to materially decline due to acquisition base + organic momentum. - Tax: effective tax ~**18%** for FY due to carry-forward losses; expected to be utilized by next year, after which tax rate rises.

---

Cross-company sector implications (what these two windows collectively indicate)

1) **Scale + density is the core competitive asset** Retail expresses it as **5,112 stores enabling <2-hour delivery**; distribution expresses it as **131 warehouses and 505 districts** with **2–3 deliveries/day**. Density lowers delivery cost, improves fill rates, and becomes a defensible moat.

2) **Private label is a structural margin lever in retail** MedPlus discloses extreme PL pharma net margins (**~65–70%**) and meaningful PL non-pharma margins (**~25–28%**), with PL share already **22.2% of revenue**. This suggests organized retailers can expand gross margin without relying on price inflation—though pharma PL substitution is capped by prescriptions.

3) **Working-capital excellence is a winning determinant in both models** Retail must manage the **103-day Year‑1 store inventory** drag; distribution must compress **~60+ day** NWC while scaling. Both explicitly target/improve working capital, tying directly to OCF and ROCE.

4) **Regulatory noise (wage codes, GST) is real but treated as manageable** Both firms booked wage code costs (₹70.59m and ₹8.2cr exceptional). Both also highlighted GST effects—on growth comparability (retail) and on NWC reporting (distribution). The sector will likely continue seeing periodic accounting/comparability distortions driven by policy changes.

5) **Consolidation is accelerating—especially in distribution** Entero’s data explicitly quantifies the consolidation thesis: large distributors’ share projected to move from **8–10% (FY23)** to **20–30% (FY28)**. If realized, scale players may grow far above underlying demand growth, with M&A and integration capability becoming a primary differentiator.

---